Recital 2, Regulation (EU) 2025/2086

In forcesince 17 Oct 2025

Pursuant to Commission Implementing Regulation (EU) 2024/2699 [Commission Implementing Regulation (EU) 2024/2699 of 18 October 2024 laying down, pursuant to Regulation (EU) 2021/2282 of the European Parliament and of the Council, detailed procedural rules for the cooperation of the Member State Coordination Group on Health Technology Assessment and the Commission with the European Medicines Agency in the form of exchange of information as regards the joint clinical assessment of medicinal products and medical devices and in vitro diagnostic medical devices and as regards the joint scientific consultation on medicinal products and medical devices (OJ L, 2024/2699, 21.10.2024, ELI: http://data.europa.eu/eli/reg_impl/2024/2699/oj).], the European Medicines Agency is to provide the Commission acting as secretariat of the Coordination Group (‘the HTA secretariat’) with information on all medical devices for which the expert panels provided a scientific opinion or their views no later than 15 days after the end of each quarter, pertaining to that quarter.